Table 2.

Base-case and scenario analysis results for AMS versus usual care in Ethiopia

	Pharmacist-led AMS	Usual care	Incremental
Base-case analysis
Base-case (discounted rate 3%)
Life years	17.91	17.86	0.05
QALY	13.2772	13.2384	0.0388
Cost	42.00	124.37	−82.37
ICER (US$/QALY)			Dominant
Base-case (discounted rate 0%)
Life-years	28.6172	28.5336	0.0836
QALY	21.2807	21.2185	0.0622
Cost	42.02	124.43	−82.41
ICER (US$/QALY)			Dominant
Scenario Analysis
Scenario 1 (discounted 3%)
Life-years	17.9025	17.87	0.0325
QALY	13.2456	13.2216	0.024
Cost	41.11	48.7	−7.59
ICER (US$/QALY)			Dominant
Scenario 2 (discounted 3%)
Life-years	17.8906	17.87	0.0205
QALY	13.2457	13.2216	0.0241
Cost	42.91	48.7	−5.79
ICER (US$/QALY)			Dominant

AMS, antimicrobial stewardship; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.